These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851 [TBL] [Abstract][Full Text] [Related]
10. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? Weller M; Reifenberger G Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376 [TBL] [Abstract][Full Text] [Related]
11. Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis. Lee K; Kim SI; Kim EE; Shim YM; Won JK; Park CK; Choi SH; Yun H; Lee H; Park SH Sci Rep; 2023 Apr; 13(1):6761. PubMed ID: 37185778 [TBL] [Abstract][Full Text] [Related]
12. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance. Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574 [TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of gliomas. Appin CL; Brat DJ Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767 [TBL] [Abstract][Full Text] [Related]
14. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
15. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156 [TBL] [Abstract][Full Text] [Related]
16. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma. Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900 [TBL] [Abstract][Full Text] [Related]
17. [Precision Medicine for IDH-mutant Diffuse Glioma(Lower-grade Glioma)]. Mukasa A No Shinkei Geka; 2022 Jan; 50(1):8-18. PubMed ID: 35169082 [TBL] [Abstract][Full Text] [Related]
18. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
19. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427 [TBL] [Abstract][Full Text] [Related]
20. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. Sonoda Y Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]